Heidi  Hunter net worth and biography

Heidi Hunter Biography and Net Worth

Director of IO Biotech

Ms. Hunter has served on our board of directors since August 2023. Ms. Hunter most recently served as President of Cardinal Health where she led the Specialty Solutions Business. Prior to Cardinal Health, Ms. Hunter was Senior Vice President of the Global Immunology Business Unit at UCB in Brussels from September 2015 to September 2020. She has also held leadership positions at Boehringer Ingelheim as Senior Vice President and General Manager in its Biosimilars Business, and at IQVIA as Vice President of Global Business Partnerships Commercial Solutions.

Ms. Hunter also held senior leadership positions in commercial and strategic marketing for biologics and oncology at Centocor, a Johnson & Johnson company. She also led the oncology business at Wyeth (today part of Pfizer) in the United States and CNS and women’s health at Novo Nordisk in Denmark. Early in Ms. Hunter’s career, she held sales and marketing positions at Ciba-Geigy in Switzerland (today part of Novartis). She is currently on the boards of Bavarian Nordic A/S, Vicore Pharma Holdings AB and Sutro Biopharma, Inc. Ms. Hunter earned a B.A. from The University of Michigan and her M.B.A. from The University of Chicago – Booth School of Business.

What is Heidi Hunter's net worth?

The estimated net worth of Heidi Hunter is at least $720.00 as of May 30th, 2025. Ms. Hunter owns 15,000 shares of IO Biotech stock worth more than $720 as of October 10th. This net worth approximation does not reflect any other investments that Ms. Hunter may own. Learn More about Heidi Hunter's net worth.

How do I contact Heidi Hunter?

The corporate mailing address for Ms. Hunter and other IO Biotech executives is , , . IO Biotech can also be reached via phone at 45-7070-2980 and via email at [email protected]. Learn More on Heidi Hunter's contact information.

Has Heidi Hunter been buying or selling shares of IO Biotech?

Heidi Hunter has not been actively trading shares of IO Biotech in the last ninety days. Most recently, on Friday, May 30th, Heidi Hunter bought 15,000 shares of IO Biotech stock. The stock was acquired at an average cost of $1.39 per share, with a total value of $20,850.00. Following the completion of the transaction, the director now directly owns 15,000 shares of the company's stock, valued at $20,850. Learn More on Heidi Hunter's trading history.

Who are IO Biotech's active insiders?

IO Biotech's insider roster includes Heidi Hunter (Director), Amy Sullivan (CFO), and Mai-Britt Zocca (Founder & CEO). Learn More on IO Biotech's active insiders.

Heidi Hunter Insider Trading History at IO Biotech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/30/2025Buy15,000$1.39$20,850.0015,000View SEC Filing Icon  
See Full Table

Heidi Hunter Buying and Selling Activity at IO Biotech

This chart shows Heidi Hunter's buying and selling at IO Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IO Biotech Company Overview

IO Biotech logo
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More

Today's Range

Now: $0.05
Low: $0.05
High: $0.05

50 Day Range

MA: $0.08
Low: $0.03
High: $0.21

2 Week Range

Now: $0.05
Low: $0.03
High: $2.79

Volume

N/A

Average Volume

7,085,531 shs

Market Capitalization

$3.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88